Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Net Cash Flow (2016 - 2025)

Marimed (MRMD) has disclosed Net Cash Flow for 14 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 191.3% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, up 121.76% year-over-year, with the annual reading at $1.6 million for FY2025, 121.76% up from the prior year.
  • Net Cash Flow for Q4 2025 was $2.3 million at Marimed, up from $458000.0 in the prior quarter.
  • The five-year high for Net Cash Flow was $11.9 million in Q1 2023, with the low at -$25.6 million in Q2 2022.
  • Average Net Cash Flow over 5 years is $294250.0, with a median of $523500.0 recorded in 2024.
  • The sharpest move saw Net Cash Flow surged 10605.47% in 2021, then plummeted 607.26% in 2022.
  • Over 5 years, Net Cash Flow stood at $4.1 million in 2021, then tumbled by 133.54% to -$1.4 million in 2022, then surged by 200.73% to $1.4 million in 2023, then crashed by 280.81% to -$2.5 million in 2024, then surged by 191.3% to $2.3 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $2.3 million, $458000.0, and -$1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.